A Study of the Safety and Efficacy of Prime Editing (PM577) in Participants With Wilson Disease (WD)

计划入组 42 人 · 首次发布于 2026 年 8 月 5 日

A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )

计划入组 12 人 · 首次发布于 2024 年 8 月 19 日

OpSens PRIME CLASS

计划入组 32 人 · 首次发布于 2021 年 10 月 7 日

PKU in vivo prime editing therapy(University of Zurich)

Gene editing therapies(Myeloid Therapeutics/Prime Medicine)

SERPINA1 gene editing therapy (Korro Bio/Genevant Sciences)

PRIME MEDICINE

India

Prime Commerce, LLC

United States

Prime Potions Inc

Canada

Prime Medicine Reports Breakthrough Clinical Data for First Prime Editing Therapy in Chronic Granulomatous Disease

Prime Medicine Reports First-in-Human Prime Editing Success for Chronic Granulomatous Disease in NEJM

Base and Prime Editing Scan EGFR Variants for Drug Response